PFG Private Wealth Management LLC Makes New Investment in Moderna, Inc. $MRNA

PFG Private Wealth Management LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,458 shares of the company’s stock, valued at approximately $473,000.

Several other hedge funds also recently bought and sold shares of MRNA. BlackRock Inc. bought a new position in shares of Moderna in the 2nd quarter valued at approximately $2,142,877,000. Theleme Partners LLP acquired a new stake in Moderna in the 2nd quarter worth approximately $564,272,000. Merck & Co. Inc. acquired a new stake in Moderna in the 2nd quarter worth approximately $161,642,545. Bamco Inc. NY bought a new stake in Moderna during the second quarter worth approximately $139,317,000. Finally, Bank of New York Mellon Corp bought a new stake in Moderna during the second quarter worth approximately $119,168,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on MRNA shares. JPMorgan Chase & Co. lifted their price target on shares of Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Morgan Stanley upped their price objective on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Berenberg Bank lifted their price target on Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research report on Friday, September 11th. Singular Research upgraded Moderna to a “hold” rating in a report on Wednesday, September 23rd. Finally, Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and increased their price objective for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $101.45.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna rallied as money moved from popular technology shares into healthcare. The move was notably stronger than gains among other major mRNA companies, suggesting renewed investor interest in Moderna. Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
• Positive Sentiment: Merck CEO Rob Davis said the companies expect their breakthrough cancer vaccine to become faster to manufacture over time. He described the manufacturing process as complex but said Merck and Moderna have refined it substantially, supporting optimism about potential commercialization. Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
• Neutral Sentiment: Investor enthusiasm for Moderna’s cancer-vaccine opportunity has helped drive a dramatic year-to-date rally. However, the coverage cautions that the stock’s valuation may already reflect substantial future success, increasing the risk of volatility if development or commercial progress disappoints. Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
• Negative Sentiment: Goldman Sachs raised its Moderna price target from $120 to $137 but maintained a Neutral rating. The revised target remains well below the current trading level, signaling that the bank views the recent rally as ahead of its fundamental valuation. Goldman Sachs raises Moderna price target

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of the business’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares in the company, valued at $219,921,913.54. This trade represents a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 118,882 shares of company stock valued at $16,862,280 over the last ninety days. 10.80% of the stock is owned by company insiders.

Moderna Stock Performance

MRNA stock traded up $11.80 during trading on Thursday, reaching $238.10. 11,761,500 shares of the stock were exchanged, compared to its average volume of 12,269,985. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $242.29. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $95.06 billion, a P/E ratio of -29.75 and a beta of 1.09. The stock has a 50 day simple moving average of $149.83 and a 200-day simple moving average of $88.67.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the firm posted ($2.13) EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.